PCSK9 and Hypercholesterolemia: Currently, PCSK9 monoclonal antibodies include alirocumab and evolocumab, which are approved by the US Food and Drug Administration (FDA) for the treatment of hypercholesterolemia, including primary hypercholesterolemia and familial hypercholesterolemia.